Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

Autor: Kristin Baird, John Glod, Seth M. Steinberg, Denise Reinke, Joseph G. Pressey, Leo Mascarenhas, Noah Federman, Neyssa Marina, Sant Chawla, Joanne P. Lagmay, John Goldberg, Mohammed Milhem, David M. Loeb, James E. Butrynski, Brian Turpin, Arthur Staddon, Sheri L. Spunt, Robin L. Jones, Eve T. Rodler, Scott M. Schuetze, Scott H. Okuno, Lee Helman

Publikováno v: Sarcoma, Vol 2020 (2020)

Purpose. Osteosarcoma is a rare cancer and a third of patients who have completed primary treatment will develop osteosarcoma recurrence. The Src pathway has been implicated in the metastatic behavior of osteosarcoma; about 95% of samples examined ex

Externí odkaz: https://doaj.org/article/167aeada11894cf68e9583bfc2edd879

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

Autor: Saskia Litière, J.-Y. Blay, J.M. Kerst, F. Collin, Sandrine Marreaud, Nicolas Penel, James E. Butrynski, B. Bui-Nguyen, Mohammed M. Milhem, Anna K.L. Reyners, N. Isambert, W.T.A. van der Graaf

Publikováno v: European Journal of Cancer, 51, 1312-20
European Journal of Cancer, 51, 10, pp. 1312-20
European Journal of Cancer, 51(10), 1312-1320. ELSEVIER SCI LTD

Purpose: To evaluate whether trabectedin as first-line chemotherapy for advanced/metastatic soft tissue sarcoma prolongs progression-free survival (PFS), compared to doxorubicin and, in the phase IIb part here, to select the most appropriate trabecte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a64359363327b7c1ea3b37f7742b78d
https://doi.org/10.1016/j.ejca.2015.03.023

Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Autor: William Jeffery Edenfield, Gozde Colak, Neal D. Shore, Gurkamal Chatta, Claudia Lebedinsky, Satish Shah, William Oh, Mary-Ellen Taplin, Luke T. Nordquist, Arif Hussain, Jian Li, Oliver Sartor, Adrian M. Senderowicz, Emmanuel S. Antonarakis, Patrick Trojer, Manojkumar Bupathi, William D. Bradley, James E. Butrynski, Manish Agrawal, David Nash, William R. Clark, Mark D. Fleming, Jessica Piel, David R. Wise

Publikováno v: Cancer Research. 79:CT094-CT094

Background: Increased expression and neomorphic mutations of the histone methyltransferase EZH2 are often observed in cancer, leading to repression of genes associated with apoptosis and differentiation. High EZH2 expression and low expression of EZH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cddf354b2fe3674780acff5a64133094
https://doi.org/10.1158/1538-7445.am2019-ct094

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

Autor: Andrew J. Wagner, Carolyn N. Krasner, David C. Harmon, Jeffrey A. Morgan, Marisa R. Nucci, Judith Manola, Nikhil H. Ramaiya, Richard T. Penson, Richard Quek, George D. Demetri, Suzanne George, James E. Butrynski, Yang Feng

Publikováno v: Cancer. 120:738-743

BACKGROUND Advanced uterine leiomyosarcoma (ULMS) is an incurable disease. A significant percentage of cases of ULMS express estrogen and/or progesterone receptors (ER and/or PR). To the authors' knowledge, the role of estrogen suppression in disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::999d927574be3f573b3f838af904690e
https://doi.org/10.1002/cncr.28476

Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

Autor: Jonathan A. Fletcher, Sarah Solomon, Jeffrey T. Yap, Jeffrey A. Morgan, Qian Wang, Margaret von Mehren, Judith Manola, William D. Tap, Christopher L. Corless, James E. Butrynski, Meijun Zhu, Michael Heinrich, Andrew J. Wagner, George D. Demetri, Edwin Choy, Annick D. Van den Abbeele, Suzanne George

Publikováno v: Journal of Clinical Oncology. 30:2401-2407

Purpose Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib. Regorafenib is a structurally unique inhibitor of multiple cancer-associated kinases, including KIT a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3445eea7f23413dc35d873dca1b04f
https://doi.org/10.1200/jco.2011.39.9394